CLEVER HANDELN

Richten Sie Börsennews.de als Startseite ein

Hier klicken

BIOINVENT Aktie

BIOINVENT INTERNATIONAL AB NAMN-AKTIER SK -,50

ISIN: SE0000789711

 | 

WKN: 677134

 | 

Symbol: BIX

 | 

Land: Schweden


1,56 EUR 0,0000%

Die besten Rohstoffaktien der Welt

Zu Ihrem Onlinebroker

kaufen verkaufen
Deutsche Bank DAB bank AG OnVista Bank ViTrade 1822direkt flatex S Broker comdirect ING DiBa Sino Cortal Consors maxblue TARGOBANK alle vergleichen
Deutsche Bank DAB bank AG OnVista Bank ViTrade 1822direkt flatex S Broker comdirect ING DiBa Sino Cortal Consors maxblue TARGOBANK alle vergleichen

BIOINVENT Aktienkurs

: 11:11 ( 15 Min. verzögert)
1,56 €
Letzter Kurs
 0,00%
Veränderung
 1,56 €
Vortag
 1,56 €
Eröffnungskurs

Alle News aus dem Web zur BIOINVENT Aktie

  • 24.05.

    Vitrolife named as winner of the 2012 SwedenBIO Award

    This year's prize is the sixth to be awarded and previous winners are Aerocrine, BioInvent, Cellavision, Medivir and Gyros. “We are extremely proud to have been awarded this distinction. We see the award as a...

  • 10.05.

    ThromboGenics NV - Business Update

    ThromboGenics is also developing two novel antibody therapeutics in collaboration with BioInvent International. These are TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer,...

  • 10.05.

    ThromboGenics NV - Business Update

    ThromboGenics is also developing two novel antibody therapeutics in collaboration with BioInvent International. These are TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer,...

  • 10.05.

    ThromboGenics NV - Business Update

    ThromboGenics is also developing two novel antibody therapeutics in collaboration with BioInvent International. These are TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer,...

  • 09.05.

    Drug Delays Relapse in Multiple Myeloma

    ... trial. Attal reported financial links with Celgene and Jansen. The editorial author reported financial links with Pfizer, AOI, Onyx, Bristol-Myers Squibb, BioInvent, Geron, and Lilly.